Anna Protopapas
Net Worth

Last updated:

What is Anna Protopapas net worth?

The estimated net worth of Ms. Anna Protopapas is at least $8,139,798 as of 16 Jan 2024. She owns shares worth $908,561 as insider, has earned $179,237 from insider trading and has received compensation worth at least $7,052,000 in Mersana Therapeutics, Inc..

What is the salary of Anna Protopapas?

Ms. Anna Protopapas salary is $881,500 per year as Pres, Chief Executive Officer & Director in Mersana Therapeutics, Inc..

How old is Anna Protopapas?

Ms. Anna Protopapas is 61 years old, born in 1964.

What stocks does Anna Protopapas currently own?

As insider, Ms. Anna Protopapas owns shares in one company:

Company Title Shares Price per share Total value
Mersana Therapeutics, Inc. (MRSN) Pres, Chief Executive Officer & Director 125,153 $7.26 $908,561

What does Mersana Therapeutics, Inc. do?

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

MRSN logo
MRSN
Mersana Therapeutics, Inc.
$7.26

Anna Protopapas insider trading

Mersana Therapeutics, Inc.

Ms. Anna Protopapas has made 4 insider trades between 2017-2024, according to the Form 4 filled with the SEC. Most recently she sold 29,399 units of MRSN stock worth $79,671 on 16 Jan 2024.

The largest trade she's ever made was exercising 100,000 units of MRSN stock on 15 Jul 2021. As of 16 Jan 2024 she still owns at least 125,153 units of MRSN stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 29,399 $2.71 $79,671
Option
Common Stock 17,708 N/A N/A
Option
Restricted Stock Unit 17,708 N/A N/A
Option
Common Stock 21,250 N/A N/A
Option
Restricted Stock Unit 21,250 N/A N/A
Option
Restricted Stock Unit 16,750 N/A N/A
Option
Common Stock 16,750 N/A N/A
Option
Restricted Stock Unit 31,250 N/A N/A
Option
Common Stock 31,250 N/A N/A
Sale
Common Stock 17,346 $5.74 $99,566
Option
Common Stock 21,250 N/A N/A
Option
Common Stock 17,708 N/A N/A
Option
Restricted stock unit 21,250 N/A N/A
Option
Restricted stock unit 17,708 N/A N/A
Option
Common Stock 16,750 N/A N/A
Option
Restricted stock unit 16,750 N/A N/A
Option
Common Stock 38,958 N/A N/A
Option
Restricted Stock Units 17,708 N/A N/A
Option
Restricted Stock Units 21,250 N/A N/A
Sale
Common Stock 21,901 N/A N/A
Sale
Common Stock 20,043 N/A N/A
Option
Common Stock 100,000 N/A N/A
Option
Restricted Stock Units 100,000 N/A N/A
Option
Restricted Stock Units 17,709 N/A N/A
Option
Common Stock 17,709 $21.09 $373,483
Option
Common Stock 10,417 N/A N/A
Option
Option to Purchase Common Stock 10,417 N/A N/A

Mersana Therapeutics key executives

Mersana Therapeutics, Inc. executives and other stock owners filed with the SEC: